Replies to post #330701 on Avid Bioservices Inc (CDMO)

[ViaRoble]

Can someone explain why Roger, who was CEO for less than two years, got a full one year out package? Plus relocation and relocation bonus?

I guess failure has its rewards.

The "New PD Lab" could have used some equipment that is actually New with the money we spent on his "Personal Reasons" for leaving so abruptly.

[north40000]

Among the reasons for that tear and wait?:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149427070

"Target number of overall survival events reached.

On June 12, 2019, Halozyme Therapeutics, Inc., a Delaware corporation (“Halozyme”), announced that it had reached the target number of 330 overall survival events in its HALO-301clinical trial and that it plans to conduct the final overall survival analysis upon data maturity which will occur when all patients enrolled in the study have been followed for at least 8.5 months. Accordingly, Halozyme projects to achieve data maturity in mid-September 2019. Based on this timing of data maturity, Halozyme expects to announce top line results for the HALO-301clinical trial by December 2019."